HomeCompareVCCBF vs PFE

VCCBF vs PFE: Dividend Comparison 2026

VCCBF yields 0.86% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $29.7K in total portfolio value· pulled ahead in Year 8
10 years
VCCBF
VCCBF
● Live price
0.86%
Share price
$3.34
Annual div
$0.03
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19.8K
Annual income
$0.08
Full VCCBF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — VCCBF vs PFE

📍 PFE pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVCCBFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VCCBF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VCCBF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VCCBF
Annual income on $10K today (after 15% tax)
$72.77/yr
After 10yr DRIP, annual income (after tax)
$0.07/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $22,319.84/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VCCBF + PFE for your $10,000?

VCCBF: 50%PFE: 50%
100% PFE50/50100% VCCBF
Portfolio after 10yr
$34.7K
Annual income
$13,129.40/yr
Blended yield
37.85%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

VCCBF
No analyst data
Altman Z
-0.1
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VCCBF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVCCBFPFE
Forward yield0.86%6.13%
Annual dividend / share$0.03$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%13.2%
Portfolio after 10y$19.8K$49.6K
Annual income after 10y$0.08$26,258.71
Total dividends collected$86.00$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: VCCBF vs PFE ($10,000, DRIP)

YearVCCBF PortfolioVCCBF Income/yrPFE PortfolioPFE Income/yrGap
1$10,743$42.80$9,153$693.39+$1.6KVCCBF
2$11,516$21.49$8,593$849.25+$2.9KVCCBF
3$12,333$10.76$8,336$1,066.78+$4.0KVCCBF
4$13,202$5.39$8,437$1,384.80+$4.8KVCCBF
5$14,129$2.69$9,013$1,875.40+$5.1KVCCBF
6$15,119$1.35$10,306$2,680.72+$4.8KVCCBF
7$16,178$0.67$12,820$4,101.38+$3.4KVCCBF
8← crossover$17,311$0.34$17,673$6,826.70$362.00PFE
9$18,523$0.17$27,543$12,591.86$9.0KPFE
10$19,820$0.08$49,560$26,258.71$29.7KPFE

VCCBF vs PFE: Complete Analysis 2026

VCCBFStock

V-cube, Inc. develops and provides visual communication services to enterprise customers. The company offers V-CUBE Meeting, a cloud-based Web conferencing service; V-CUBE Seminar, a Web seminar product for seminars, training, and information sessions; V-CUBE Sales, a web conferencing tool for online sales; V-CUBE Learning, a learning management system (LMS) that has incorporated the virtual online platform for training and learning purposes; and V-CUBE Voice, a teleconferencing service. It also provides Telecube, a soundproof smartphone box that can be installed anywhere and there are tables and chairs, and a PC inside that can be used for web conferencing; QUMU, a cloud-type video distribution management system; Agora for implementation of video calls and live distribution on iOS/Android applications and websites; EventIn, an online event platform; V-CUBE Collaboration, a web conferencing service to share video and audio, and PC desktop screens in real-time; and Realwear explosion-proof smart glass. In addition, the company offers hardware related to visual communication, such as web cameras, headsets, microphones with echo cancellers, large LCD displays, etc., as well as post-installation management services. V-cube, Inc. was founded in 1998 and is headquartered in Tokyo, Japan.

Full VCCBF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this VCCBF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VCCBF vs SCHDVCCBF vs JEPIVCCBF vs OVCCBF vs KOVCCBF vs MAINVCCBF vs JNJVCCBF vs MRKVCCBF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.